While a role for oncogenic KIT in driving mast cell disease is clear, the mechanisms driving the multiple phenotypic and clinical manifestations of this disorder are not well elucidated. We now show, using a large cohort of mastocytosis patients, including an almost equal number of aggressive and non-aggressive cases of systemic mastocytosis, that in contrast to the oncogenic KITD816V, TET2 mutation statistically associates with aggressive forms of the disease. By infecting primary murine bone marrow-derived mast cells with KITD816V, we also observe a significant and competitive growth advantage for KITD816V in Tet2-nullizygous compared to wild type cells. TET2-deficient cells display increased proliferation and can survive in absence of cytokines. Taken together, these data demonstrate a oncogenic cooperation in mast cells and reveal TET2 mutation as a potential marker to diagnose and predict severe forms of mastocytosis.
Introduction
Mastocytosis is a rare heterogeneous disease characterized by accumulation of morphologically and phenotypically abnormal mast cells (MC) in one or several organs. A WHO classification describes several subcategories of this disease broadly divided into localized or systemic disease 1 . Systemic disease is subsequently divided into indolent and aggressive disease. Aggressive disease is defined by the impairment of at least one organ due to damage produced by the local mast cell infiltrate (C-finding) and rarely involves the skin.
Mast cell neoplasms are also related to the clonal proliferation of mast cells secondary to a gain-of-function of KIT, a tyrosine kinase receptor, which results in constitutive signalling 2, 3 . The majority of adults with mastocytosis present KIT tyrosine kinase domain mutations, most frequently D816V 4 . Recent work has provided insight into the causative role of the D816V mutation in differentiation and abnormal clustering of neoplastic cells 5 and in induction of mastocytosis 6 . Nonetheless, the KITD816V mutation is prevalent in both aggressive and non-aggressive mastocytosis and does not correlate with either form of the disease. Expression of KITD816V alone is unable to transform primary hematopoietic cells 7, 8 . The clonal nature of mast cell disorders also suggests that KITD816V alone is insufficient to fully transform mast cells in vivo 6 . Taken together, the development, some clinical manifestations and the severity of disease are likely determined by additional mutations.
TET2 is a tumour suppressor gene whose product has been suggested to play an important enzymatic role in DNA demethylation [9] [10] [11] . Loss-of-function mutations, including mutations affecting the catalytic domain of this protein have been documented in a number of different hematopoietic tumours and myeloproliferative neoplasms [12] [13] [14] [15] . Given the current lack molecular markers to monitor and predict the clinical course of mastocytosis, we screened a large cohort of mastocytosis patients to determine the prevalence of TET2 mutations and if these mutations could be associated with KITD816V and aggressive disease.
Materials and Methods
Patient data is detailed in Supplementary Table1. Mutation analysis for KIT and TET2 has been described 12, 16 . Lentiviral infection and culture of bone marrow mast cells (BMMCs) have been described 17 . Expression analysis was done by standard quantitative-real-time-PCR using PowerSYBR and a 7500 Fast Real-Time System (Applied Biosystem). Primers are described elsewhere 11 . All patients were included in "Mastocytosis Pathophysiological Study", which started in 2003 and is sponsored by the Association-for-Initiative-and-Research-on-Mastocyte-and-Mastocytosis (AFIRMM). The study was approved by Necker Hospital ethical committee, and carried out according to the Helsinki convention. Each patient provided informed consent.
Results and Discussion
Our cohort consisted of 74 mastocytosis patients, categorized according to the WHO classification for aggressive or non-aggressive disease 7 . Consistent with previous studies, the majority of these patients, 82.5%, were positive for KIT mutation, 78.4% 18 . Two distinct mutations in the TET2 gene were detected some patients and in all cases TET2 mutation occurred in conjunction with KIT mutation (SupTable1.0). Importantly, TET2 mutation correlated significantly to aggressive forms of mastocytosis (p=0.003) (Fig1). Both TET2 and KIT mutations were found in primary mast cells sorted from patients and clonal analysis from bone marrow biopsies of two patients were also consistent with a model where TET2 mutation is an early event that precedes clonal disease onset of aggressive disease (SupFig1). Finally, cells from a patient with homozygous TET2-mutation responded normally to TKIs (SupFig2).
To investigate whether TET2-deficiency and KITD816V could cooperate to transform primary mast cells, we obtained bone marrow from two different TET2-deficient mouse lines 19 . We then differentiated in vitro bone marrow progenitors from either wild type or TET2-deficient animals towards the mast cell lineage. All bone marrow mast cell (BMMC) cultures were homogenous for mature mast cell markers including expression of high levels of endogenous murine CD117, FcεR1a and mast cell proteases (SupFigs3-4). Thus, TET2-deficiency does not appear to overtly corrupt mast cell differentiation.
Strikingly, upon infection of these BMMC cultures with lentivirus coding for KITD816V and a GFP tracer (Fig2A), we observed a rapid and specific selection for KITD816V-positive cells in TET2-deficient cultures (Fig2B). This result was reproducible in primary mast cells derived from both mouse models and also in BMMCs, infected with KITD816V after 80 days of in vitro culture in the presence of IL3 (SupFig5), arguing against a bias due to enrichment for infection of stem or progenitor cells whose levels are reportedly higher in the bone marrow TET2-deficient animals 19, 20 . We also observed a small but significant increase in BrdU incorporation for both Tet2 (+/-) and Tet2
KITD816V positive populations (Fig2C), providing an explanation for the competitive growth advantage of these cells. In contrast to wild type primary BMMCs, TET2-deficient BMMCs infected with KITD816V could survive for over three weeks in the absence of IL3 (Fig2D,E) . Analysis of surviving cells revealed enrichment for KITD816V (Fig2F) and a capacity for cell division in the absence of IL3 (Fig2G). However, unlike BMMCs derived from transgenic KITD816V mice that select for secondary mutations in culture 6 , we were unable to render TET2-deficient/KITD816V+ cells completely independent of growth factors within the timeframe of these experiments. Overall, our in vitro results are consistent with the transformed phenotype of mast cells in patients; even aggressive forms of systemic mastocytosis are considered to be neoplastic but not malignant.
A high frequency of TET2 mutations has been reported in patients with SM 15 . We now confirm these observations and show a significant correlation between TET2 mutation and aggressive forms of the disease, but, unlike this earlier study, we do not detect an association between TET2 mutation and specific AHNMDs. We have been able to observe both TET2 and KITD816V in the primary mast cells from these patients strongly suggesting an oncogenic cooperation. In vitro analysis indicate that KITD816V
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Overall our data provide a novel insight into aggressive mast cell disease in patients presenting with TET2 mutations and, importantly, provide a new marker for the diagnosis and treatment of these chronic disorders. At a molecular level, our data also support a model wherein mutations that incur epigenetic deregulation can promote more severe forms of mast cell disease in conjunction oncogenic activation of KIT. Whether this mechanism also play a role in other malignant situations with co-occurrence of TET2 inactivation and tyrosine kinase activation, such as in other myeloproliferative neoplasms, need to be investigated. 
